Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002332
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of Timunox Thymopentin in HIV-Infected Patients Receiving Other Anti-HIV Drugs
Sponsor:
Immunobiology Research Institute
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Double-Blind Study of the Effect of Timunox Thymopentin on Lymphoproliferative Responses and Virus Load in HIV-Infected Subjects Receiving Nucleoside Analog Antiretroviral Therapy
Status:
COMPLETED
Status Verified Date:
1995-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection
Detailed Description:
Patients are randomized to receive subcutaneous thymopentin or placebo thrice weekly for 4 weeks
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 0732039-94 | None | None | None |